Immunic, Inc.
imux.comWhat Do They Do?
Develops oral drug candidates for neurologic and gastrointestinal diseases, including multiple sclerosis and intestinal disorders, for patients with chronic inflammatory and autoimmune diseases.
10-K for FY2025, filed Feb 26, 2026
Sources
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
Sources
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$34.1MView ↗
- ▲ +27% (Loss)
- vs −$26.8M in Q2 FY2025
-
May 27, 2026
Immunic appointed Erik Lundgren as chief executive officer
He succeeded Daniel Vitt, who retained responsibility for scientific strategy and portfolio advancement.
Sources
8-K, filed May 27, 2026
Appointment of Erik Lundgren as Chief Executive OfficerView ↗
Loading...
Comments
